Omega-3 Supplement Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Omega-3 supplement sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹2.7 crore - ₹41 crore CapEx this DPR captures:

• Bio-medical waste authorisation under BMW Rules 2016
• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The Indian Omega-3 supplement industry operates across a structured sectoral landscape that spans marine-based fish oil, algal oil, and plant-based flaxseed and ALA sources. The overall dietary supplements market in India was valued at USD 177.9 billion as of 2024, providing a substantial downstream retail ecosystem for Omega-3 products. Within the Omega-3 segment, marine-based sources including fish oil, krill oil, and algal oil remain dominant, but the non-fish and plant-based category is emerging as the fastest-growing sub-segment, with a projected compound annual growth rate of 6.8% through 2035 according to Fact.MR.

The algal segment alone holds approximately 70.0% share of the non-fish alternative market, while flaxseed-based options command 20.0% share, as of 2025.</p><p>India's engagement in global marine oil trade is significant, with the country ranked ninth globally in fish and marine oil exports, recording an export value of USD 103,922,712 in 2023, up dramatically from USD 3,220,686 in 2019. Export price ranges for these products spanned USD 1.40 to USD 6.10 per kilogram in 2023. The domestic market is bifurcated into organized and unorganized segments, with the organized sector commanding approximately 65% to 70% of the total dietary supplement market share.

Import growth for EPA and DHA shipments into India has been explosive, registering a 27.1% compound annual growth rate, signaling that domestic supply is struggling to keep pace with accelerating demand. The broader non-fish omega-3 supplements market globally is projected to grow from USD 1.4 billion in 2025 to USD 2.5 billion by 2035 at a 6.0% CAGR, while the plant-based omega-3 supplements market specifically is forecast to reach USD 18.83 billion by 2033 from a starting value of USD 10.02 billion in 2025, registering an 8.20% CAGR according to Data Bridge Market Research.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>Modern Omega-3 supplement manufacturing in India is increasingly built around industrial-scale heterotrophic fermentation as the core production technology. This process involves the controlled culturing of marine microorganisms belonging to the families Thraustochytriaceae and Crypthecodiniaceae within closed bioreactor systems, replacing older open-pond cultivation methods that are prone to contamination and yield inconsistency. The heterotrophic approach delivers superior purity, scalability, and batch-to-batch consistency, and it has become the preferred platform for algal DHA and EPA production at commercial volumes.</p><p>The downstream processing chain relies on enzymatic cell disruption to break open algal cell walls, followed by continuous solvent extraction to isolate the Omega-3-rich lipid fraction, and thin-film continuous deodorization to remove volatile compounds that contribute to the characteristic fishy odor and taste associated with marine-derived products.

These combined steps yield a finished oil product suitable for encapsulation into softgels or formulation into gummy delivery formats. From a sustainability standpoint, Corbion reported in 2026 that its industrial-scale microalgae fermentation process for AlgaPrime DHA reduced climate change impacts by 18% to 23% and water use by 44% to 54% per kilogram of DHA produced compared to 2021 baselines. The company's facility in Orindiúva, Brazil, leverages co-located sugarcane bagasse as a renewable energy and feedstock source, illustrating the environmental credentials that can be built into algal Omega-3 production.

This sustainability profile is a significant commercial asset given the growing consumer preference for plant-based and environmentally responsible products in India's urban markets.</p>

KAMRIT recommends a capital structure of 70 percent debt and 30 percent equity for projects in the ₹8 crore to ₹20 crore mid-scale band, shifting to 60:40 debt-equity for large-scale integrated facilities above ₹20 crore where project risk is elevated by technology commissioning timelines.

Term loan financing is available from multiple institutional sources. State Bank of India offers the SBI Healthcare Plus scheme with interest rates starting at 8.75 percent for projects above ₹5 crore, with collateral requirements of 1.25 times the loan amount. HDFC Bank's Commercial Vehicle and Equipment Finance vertical provides ₹2 crore to ₹15 crore term loans at 9-10.5 percent with 5-7 year tenures. SIDBI's Credit Support Scheme for MSMEs provides subordinate debt component of up to ₹5 crore at 3 percent below market rate for technology-upgrade components.

For projects leveraging the PLI Bulk Drugs scheme, NABARD refinance support is available through eligible state-level financial institutions at 5.5-6.5 percent for the PLI-linked component. EXIM Bank extends pre-shipment and post-shipment credit for export-oriented production at 7-8 percent LIBOR-adjusted, with packing credit facilities for inventory financing of US-bound shipments under ANDA pathways.

Working capital requirements for a ₹15 crore project are estimated at ₹4-5 crore, encompassing 45-60 days of raw material inventory (crude fish oil at ₹800-1,200 per kg), 30-day finished goods buffer, and 60-day receivables cycle dominated by institutional hospital and corporate wellness programme customers. Funded working capital limits sanctioned by banks typically cover 20-25 percent of the sanctioned term loan amount.

The ₹2.7 crore to ₹41 crore CapEx envelope translates to payback periods of 2.6 to 5.4 years depending on scale and product mix. Projects at the lower CapEx band with toll-manufactured concentrate achieve faster payback through reduced fixed costs, while integrated facilities benefit from concentrate margin capture but face longer technology ramp-up periods. Breakeven occupancy for viable project returns is estimated at 45-55 percent of rated capacity, achievable within 18-24 months given the demand growth trajectory.

Tax optimisation through Section 80-IB benefits for manufacturing facilities located in designated backward districts or through Electronics Manufacturing Cluster incentives in states including Gujarat, Tamil Nadu, and Maharashtra reduces effective post-tax cost of capital by 150-200 basis points.

<p>The primary risk facing an Omega-3 supplement plant in India is raw material cost volatility, which constitutes 70% to 80% of total operating expenses according to IMARC Group data for 2026. Algae oil with 40% DHA content, the key plant-based input, is priced at up to USD 60.00 per kilogram, compared to an average wholesale fish oil price of approximately USD 14.00 per kilogram for baseline marine benchmark inputs. This significant price differential between plant-based and marine-derived inputs compresses margins for algal producers relative to fish oil manufacturers and creates exposure to commodity price fluctuations in the global algae oil market.

Any disruption in the supply chain for cultured microalgae feedstock or fermentation inputs could have a disproportionate impact on operating costs.</p><p>Regulatory and compliance risk is a persistent concern in the Indian nutraceutical and pharmaceutical manufacturing sector. Mandatory Central FSSAI licensing applies to all health supplement manufacturing units without exception, and maintaining compliance with evolving Food Safety and Standards regulations requires continuous investment in quality assurance infrastructure. The Goods and Services Tax rate of 18% applies to finished Omega-3 supplement products under HSN code 2106, adding to the cost structure.

Additionally, the 10% to 20% utilities component of operating expenses exposes facilities to energy cost volatility, which is particularly relevant given the energy-intensive nature of industrial-scale fermentation and downstream processing operations.</p><p>Market risk stems from the breadth of conflicting market size estimates across research firms, which signals a nascent and still-evolving market with unclear sizing benchmarks. While the CAGR projections of 16.1% to 10.9% across different tracking firms are encouraging, the actual addressable market for a domestic algal Omega-3 producer depends on successfully competing against established multinational supply chains led by BASF, Lonza, DSM-Firmenich, and Croda International, which have decades of formulation expertise, established brand relationships, and integrated global supply chains. The organized sector's 65% to 70% market share also means that new entrants must compete primarily against well-capitalized, regulated players rather than an fragmented unorganized market, raising the bar for go-to-market execution and product differentiation.</p>